CASI Research and Charts

CASI - CASI Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-07-29 (Delayed quote data 2025-01-06)

Last 3.08	Change ⇑ +0.13 (+4.41%)	Volume 66,267
	Open 2.88	High 3.12	Low 2.68

8EMA (Daily) 2.96	40EMA (Daily) 3.76	50EMA (Daily) 3.99	STO (Daily) 44.846	MACD Hist (Daily) 0.184
8EMA (Weekly) 3.511	40EMA (Weekly) 4.65	50EMA (Weekly) 4.61	STO (Weekly) 8.170	MACD Hist (Weekly) -0.620


Company Profile
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.